Title: Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B*
Abstract: Journal of Viral HepatitisVolume 17, Issue 1 p. 16-22 Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B* R. G. Gish, R. G. Gish Division of Hepatology and Complex GI, Physicians Foundation California Pacific Medical Center, San Francisco, CA, USASearch for more papers by this authorT.-T. Chang, T.-T. Chang National Cheng Kung University Medical College, Tainan, TaiwanSearch for more papers by this authorC.-L. Lai, C.-L. Lai Department of Medicine, University of Hong Kong, Hong Kong SAR, ChinaSearch for more papers by this authorR. De Man, R. De Man Erasmus Medical Centre, University Hospital Rotterdam, NetherlandsSearch for more papers by this authorA. Gadano, A. Gadano Hospital Italiano, Hepatologia, Buenos Aires, ArgentinaSearch for more papers by this authorF. Poordad, F. Poordad Department of Hepatology and Liver Transplantation, Cedars-Sinai Medical Center, Los Angeles, CA, USASearch for more papers by this authorJ. Yang, J. Yang Bristol-Myers Squibb Company, Research and Development, Princeton, NJ, USASearch for more papers by this authorH. Brett-Smith, H. Brett-Smith Bristol-Myers Squibb Company, Research and Development, Princeton, NJ, USASearch for more papers by this authorR. Tamez, R. Tamez Bristol-Myers Squibb Company, Research and Development, Princeton, NJ, USASearch for more papers by this author R. G. Gish, R. G. Gish Division of Hepatology and Complex GI, Physicians Foundation California Pacific Medical Center, San Francisco, CA, USASearch for more papers by this authorT.-T. Chang, T.-T. Chang National Cheng Kung University Medical College, Tainan, TaiwanSearch for more papers by this authorC.-L. Lai, C.-L. Lai Department of Medicine, University of Hong Kong, Hong Kong SAR, ChinaSearch for more papers by this authorR. De Man, R. De Man Erasmus Medical Centre, University Hospital Rotterdam, NetherlandsSearch for more papers by this authorA. Gadano, A. Gadano Hospital Italiano, Hepatologia, Buenos Aires, ArgentinaSearch for more papers by this authorF. Poordad, F. Poordad Department of Hepatology and Liver Transplantation, Cedars-Sinai Medical Center, Los Angeles, CA, USASearch for more papers by this authorJ. Yang, J. Yang Bristol-Myers Squibb Company, Research and Development, Princeton, NJ, USASearch for more papers by this authorH. Brett-Smith, H. Brett-Smith Bristol-Myers Squibb Company, Research and Development, Princeton, NJ, USASearch for more papers by this authorR. Tamez, R. Tamez Bristol-Myers Squibb Company, Research and Development, Princeton, NJ, USASearch for more papers by this author First published: 14 December 2009 https://doi.org/10.1111/j.1365-2893.2009.01146.xCitations: 99 Robert G. Gish, Division of Hepatology and Complex GI, Physician Foundation California Pacific Medical Center, 2340 Clay Street, San Francisco, CA 94115-1932, USA. E-mail: [email protected] * Presented in part at the 57th Annual Meeting of the American Association for the Study of Liver Diseases, October 27–31, 2006. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract Summary. This retrospective analysis was conducted to describe the characteristics of nucleoside-naïve hepatitis B e antigen (HBeAg)-positive patients with chronic hepatitis B, who achieved hepatitis B surface antigen (HBsAg) loss during entecavir or lamivudine therapy. HBeAg-positive adults with chronic hepatitis B, elevated serum alanine aminotransferase, and compensated liver disease were randomized to double-blind treatment for up to 96 weeks with entecavir 0.5 mg/day or lamivudine 100 mg/day. HBsAg and hepatitis B virus (HBV) DNA were measured at regular intervals during and off-treatment follow-up. Through a maximum duration of 96 weeks on-treatment and 24 weeks off-treatment, HBsAg loss was confirmed in 18/354 (5.1%) patients treated with entecavir and 10/355 (2.8%) patients treated with lamivudine. Among the 28 patients with confirmed HBsAg loss, 27 (96%) achieved HBV DNA <300 copies/mL, and 27 (96%) achieved confirmed HBeAg loss. All entecavir recipients with HBsAg loss had HBV DNA <300 copies/mL. Caucasian patients, and those infected with HBV genotype A or D, were significantly more likely to lose HBsAg. This retrospective analysis of data from a randomized, global phase three trial shows that confirmed loss of HBsAg occurred in 5% of nucleoside-naïve HBeAg-positive patients treated with entecavir, and that HBsAg loss is associated with sustained off-treatment suppression of HBV DNA. Citing Literature Volume17, Issue1January 2010Pages 16-22 RelatedInformation
Publication Year: 2010
Publication Date: 2010-01-01
Language: en
Type: article
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 134
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot